New study results of Repatha®™ (evolocumab) in statin-intolerant patients published in Journal of the American Medical Association

Data Simultaneously Presented in Late-Breaking Session at ACC.16

Repatha Shown to Significantly Reduce LDL-C by approximately 55 per cent after 24 weeks compared to ezetimibe

/PLEASE NOTE: THIS INFORMATION IS FOR CANADIAN MEDIA ONLY/

MISSISSAUGA, ON, April 4, 2016 /CNW/ – Amgen…